Literature DB >> 224712

Dissociation between plasma, urine, and renal papillary cyclic AMP content following vasopressin and DDAVP.

M J Bia, S Dewitt, J N Forrest.   

Abstract

The effects of in vivo physiologic doses of vasopressin and 1-deamino-8-D-arginine vasopressin (DDAVP) on the cyclic AMP content of plasma, urine, and renal papillary tissue were determined in the ADH-deficient Brattleboro rat. During clearance studies, plasma cyclic AMP concentrations and both total and nephrogenous urinary cyclic AMP excretion in vasopressin- and DDAVP-treated rats were similar to the values in time-matched controls. In contrast, in situ renal papillary cyclic AMP content was higher (P less than 0.001) in both vasopressin- (35.7 +/- 3.6 pmol/mg protein) and DDAVP- (29.7 +/- 2.2 pmol/mg protein) treated rats compared to controls (15.1 +/- 1.3 pmol/mg protein). Endogenous stimulation of vasopressin by dehydration in normal rats increased both papillary cyclic AMP content (27.1 +/- 2.7 pmol/mg protein) and urine osmolality, whereas no change in papillary cyclic AMP was observed following dehydration in Brattleboro rats (13.6 +/- 0.8 pmol/mg protein) despite an increase in urine osmolality. The results demonstrate that changes in cyclic AMP following in vivo vasopressin are best demonstrated by measurement of in situ cyclic AMP content of the renal papilla, whereas total urinary cyclic AMP and nephrogenous cyclic AMP are not useful indices of tubular sensitivity to this hormone.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 224712     DOI: 10.1152/ajprenal.1979.237.3.F218

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  4 in total

1.  A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease.

Authors:  Irina Barash; Manish P Ponda; David S Goldfarb; Edward Y Skolnik
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-18       Impact factor: 8.237

2.  Congenital nephrogenic diabetes insipidus-vasopressin and prostaglandins in response to treatment with hydrochlorothiazide and indomethacin.

Authors:  W Rascher; W Rosendahl; I A Henrichs; R Maier; H W Seyberth
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

3.  A variant of nephrogenic diabetes insipidus: V2 receptor abnormality restricted to the kidney.

Authors:  N Knoers; L A Monnens
Journal:  Eur J Pediatr       Date:  1991-03       Impact factor: 3.183

4.  Patients with autosomal nephrogenic diabetes insipidus homozygous for mutations in the aquaporin 2 water-channel gene.

Authors:  A F van Lieburg; M A Verdijk; V V Knoers; A J van Essen; W Proesmans; R Mallmann; L A Monnens; B A van Oost; C H van Os; P M Deen
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.